New data by AKL Therapeutics suggests investigational oral osteoarthritis drug APPA may have a promising senotherapeutic effect with potential in other diseases of ageing

New data* presented at the 2023 Osteoarthritis Research Society International World Congress in Denver, Colorado suggest that AKL Therapeutics’ investigational oral osteoarthritis drug APPA** may have a dual effect on senescence.

Scroll to Top